

**REMARKS****Claim Amendments**

After entry of this amendment, claims 1-30 will be pending in this application. Claims 1-5 and 7-25 have been amended to improve their form. Support for the claim amendments can be found throughout the specification, *e.g.*, at paragraphs 123, 128, 131 and 146 of the published application (US2004/0230042). The claim amendments do not add any new matter to the specification. Claims 31-56 have been cancelled.

**Response to Restriction Requirement**

The Examiner has required restriction of claims 1-56 of this application under 35 U.S.C. § 121 into one of forty-two groups. In response to the restriction requirement, Applicant elects the subject matter of Group I, claims 1 and 5-30, for further prosecution in the present application. Claims 31-56, directed to non-elected inventions, have been cancelled. Cancellation of these claims is expressly without waiver of the right to file and obtain claims directed to the cancelled subject matter in divisional or continuing applications claiming priority to this application under 35 U.S.C. § 120.

Applicant respectfully submits that, as amended, claims 1-30 are directed to the same invention—a method of producing a recombinant glycoprotein comprising a desired N-glycan in a lower eukaryotic host cell comprising the step of expressing in the cell a nucleic acid encoding a mannosidase enzymatic activity. Entry of this Amendment and the examination of claims 1-30 is respectfully requested.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 06-1075, from which the undersigned is authorized to draw.

Dated: March 10, 2006

Respectfully submitted,

By 

Barbara A. Ruskin

Registration No.: 39,350

Gloria Fuentes

Registration No.: 47,580

FISH & NEAVE IP GROUP

ROPES & GRAY LLP

1251 Avenue of the Americas

New York, New York 10020

(212) 596-9000

(212) 596- 9090 (Fax)

Attorneys For Applicant